LPA and atherosclerosis: The 2018 American Heart Association (AHA)/American College of Cardiology (ACC) Blood Cholesterol guideline identifies Lp(a) as a risk enhancer that can be used to refine risk in borderline and intermediate ASCVD risk individuals [71].